
<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
        <meta name="description" content="Evidence-based clinical decision support templates for neurological diagnoses">
      
      
      
        <link rel="canonical" href="https://blondarb.github.io/neuro-plans/plans/myasthenia-gravis-new-diagnosis/">
      
      
        <link rel="prev" href="../myasthenia-gravis-crisis/">
      
      
        <link rel="next" href="../neuromuscular-respiratory-failure/">
      
      
        
      
      
      <link rel="icon" href="../../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.6.1, mkdocs-material-9.7.1">
    
    
      
        <title>Myasthenia Gravis - New Diagnosis - Neuro Clinical Plans</title>
      
    
    
      <link rel="stylesheet" href="../../assets/stylesheets/main.484c7ddc.min.css">
      
        
        <link rel="stylesheet" href="../../assets/stylesheets/palette.ab4e12ef.min.css">
      
      


    
    
      
    
    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../../assets/css/custom.css">
    
    <script>__md_scope=new URL("../..",location),__md_hash=e=>[...e].reduce(((e,_)=>(e<<5)-e+_.charCodeAt(0)),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="indigo" data-md-color-accent="indigo">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
        
        <a href="#myasthenia-gravis-new-diagnosis" class="md-skip">
          Skip to content
        </a>
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

  

<header class="md-header md-header--shadow" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href="../.." title="Neuro Clinical Plans" class="md-header__button md-logo" aria-label="Neuro Clinical Plans" data-md-component="logo">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3 3 3 0 0 0 3 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54"/></svg>

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3zm0 5h18v2H3zm0 5h18v2H3z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Neuro Clinical Plans
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Myasthenia Gravis - New Diagnosis
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="indigo" data-md-color-accent="indigo"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a4 4 0 0 0-4 4 4 4 0 0 0 4 4 4 4 0 0 0 4-4 4 4 0 0 0-4-4m0 10a6 6 0 0 1-6-6 6 6 0 0 1 6-6 6 6 0 0 1 6 6 6 6 0 0 1-6 6m8-9.31V4h-4.69L12 .69 8.69 4H4v4.69L.69 12 4 15.31V20h4.69L12 23.31 15.31 20H20v-4.69L23.31 12z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="indigo" data-md-color-accent="indigo"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 18c-.89 0-1.74-.2-2.5-.55C11.56 16.5 13 14.42 13 12s-1.44-4.5-3.5-5.45C10.26 6.2 11.11 6 12 6a6 6 0 0 1 6 6 6 6 0 0 1-6 6m8-9.31V4h-4.69L12 .69 8.69 4H4v4.69L.69 12 4 15.31V20h4.69L12 23.31 15.31 20H20v-4.69L23.31 12z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var palette=__md_get("__palette");if(palette&&palette.color){if("(prefers-color-scheme)"===palette.color.media){var media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']");palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent")}for(var[key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      
      
        <label class="md-header__button md-icon" for="__search">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.52 6.52 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5"/></svg>
        </label>
        <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.52 6.52 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12z"/></svg>
        </button>
      </nav>
      
        <div class="md-search__suggest" data-md-component="search-suggest"></div>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" tabindex="0" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
      
    
    
      <div class="md-header__source">
        <a href="https://github.com/blondarb/neuro-plans" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
  </div>
  <div class="md-source__repository">
    blondarb/neuro-plans
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    



<nav class="md-nav md-nav--primary" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href="../.." title="Neuro Clinical Plans" class="md-nav__button md-logo" aria-label="Neuro Clinical Plans" data-md-component="logo">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3 3 3 0 0 0 3 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54"/></svg>

    </a>
    Neuro Clinical Plans
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/blondarb/neuro-plans" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
  </div>
  <div class="md-source__repository">
    blondarb/neuro-plans
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../.." class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Home
  

    
  </span>
  
  

      </a>
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../../clinical/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Interactive Clinical Tool
  

    
  </span>
  
  

      </a>
    </li>
  

    
      
      
  
  
    
  
  
  
    
    
    
    
      
        
        
      
    
    
    <li class="md-nav__item md-nav__item--active md-nav__item--section md-nav__item--nested">
      
        
        
        <input class="md-nav__toggle md-toggle " type="checkbox" id="__nav_3" checked>
        
          
          <label class="md-nav__link" for="__nav_3" id="__nav_3_label" tabindex="">
            
  
  
  <span class="md-ellipsis">
    
  
    Clinical Plans
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_3_label" aria-expanded="true">
          <label class="md-nav__title" for="__nav_3">
            <span class="md-nav__icon md-icon"></span>
            
  
    Clinical Plans
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Overview
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_2" >
        
          
          <label class="md-nav__link" for="__nav_3_2" id="__nav_3_2_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Seizures & Epilepsy
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_2_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_2">
            <span class="md-nav__icon md-icon"></span>
            
  
    Seizures & Epilepsy
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../status-epilepticus/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Status Epilepticus
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../new-onset-seizure/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    New Onset Seizure
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../breakthrough-seizure/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Breakthrough Seizure
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_3" >
        
          
          <label class="md-nav__link" for="__nav_3_3" id="__nav_3_3_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Stroke & Vascular
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_3_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_3">
            <span class="md-nav__icon md-icon"></span>
            
  
    Stroke & Vascular
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../acute-ischemic-stroke/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Acute Ischemic Stroke
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../transient-ischemic-attack/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Transient Ischemic Attack
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../intracerebral-hemorrhage/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Intracerebral Hemorrhage
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../subarachnoid-hemorrhage/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Subarachnoid Hemorrhage
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
    
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--active md-nav__item--nested">
      
        
        
        <input class="md-nav__toggle md-toggle " type="checkbox" id="__nav_3_4" checked>
        
          
          <label class="md-nav__link" for="__nav_3_4" id="__nav_3_4_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Neuromuscular
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_4_label" aria-expanded="true">
          <label class="md-nav__title" for="__nav_3_4">
            <span class="md-nav__icon md-icon"></span>
            
  
    Neuromuscular
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../guillain-barre-syndrome/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Guillain-Barr√© Syndrome
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../cidp/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    CIDP
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../myasthenia-gravis-crisis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Myasthenic Crisis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
        
      
      
        <label class="md-nav__link md-nav__link--active" for="__toc">
          
  
  
  <span class="md-ellipsis">
    
  
    Myasthenia Gravis - New Diagnosis
  

    
  </span>
  
  

          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  
  <span class="md-ellipsis">
    
  
    Myasthenia Gravis - New Diagnosis
  

    
  </span>
  
  

      </a>
      
        

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
    
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#1-laboratory-workup" class="md-nav__link">
    <span class="md-ellipsis">
      
        1. LABORATORY WORKUP
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#2-diagnostic-imaging-studies" class="md-nav__link">
    <span class="md-ellipsis">
      
        2. DIAGNOSTIC IMAGING &amp; STUDIES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#3-treatment" class="md-nav__link">
    <span class="md-ellipsis">
      
        3. TREATMENT
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#4-other-recommendations" class="md-nav__link">
    <span class="md-ellipsis">
      
        4. OTHER RECOMMENDATIONS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#5-differential-diagnosis" class="md-nav__link">
    <span class="md-ellipsis">
      
        5. DIFFERENTIAL DIAGNOSIS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#6-monitoring-parameters" class="md-nav__link">
    <span class="md-ellipsis">
      
        6. MONITORING PARAMETERS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#7-disposition-criteria" class="md-nav__link">
    <span class="md-ellipsis">
      
        7. DISPOSITION CRITERIA
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#8-evidence-references" class="md-nav__link">
    <span class="md-ellipsis">
      
        8. EVIDENCE &amp; REFERENCES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#change-log" class="md-nav__link">
    <span class="md-ellipsis">
      
        CHANGE LOG
      
    </span>
  </a>
  
</li>
      
    </ul>
  
</nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../neuromuscular-respiratory-failure/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Neuromuscular Respiratory Failure
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../peripheral-neuropathy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Peripheral Neuropathy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../diabetic-neuropathy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Diabetic Neuropathy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_5" >
        
          
          <label class="md-nav__link" for="__nav_3_5" id="__nav_3_5_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    CNS Infections
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_5_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_5">
            <span class="md-nav__icon md-icon"></span>
            
  
    CNS Infections
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../bacterial-meningitis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Bacterial Meningitis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../hsv-encephalitis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    HSV Encephalitis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../autoimmune-encephalitis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Autoimmune Encephalitis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_6" >
        
          
          <label class="md-nav__link" for="__nav_3_6" id="__nav_3_6_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Spinal Emergencies
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_6_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_6">
            <span class="md-nav__icon md-icon"></span>
            
  
    Spinal Emergencies
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../acute-myelopathy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Acute Myelopathy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../spinal-cord-compression-malignant/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Spinal Cord Compression (Malignant)
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../cauda-equina-syndrome/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Cauda Equina Syndrome
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../epidural-abscess/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Epidural Abscess
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_7" >
        
          
          <label class="md-nav__link" for="__nav_3_7" id="__nav_3_7_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Neuro-Oncology
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_7_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_7">
            <span class="md-nav__icon md-icon"></span>
            
  
    Neuro-Oncology
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../brain-metastases/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Brain Metastases
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_8" >
        
          
          <label class="md-nav__link" for="__nav_3_8" id="__nav_3_8_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Critical Care
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_8_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_8">
            <span class="md-nav__icon md-icon"></span>
            
  
    Critical Care
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../elevated-icp-management/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Elevated ICP Management
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_9" >
        
          
          <label class="md-nav__link" for="__nav_3_9" id="__nav_3_9_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Demyelinating
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_9_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_9">
            <span class="md-nav__icon md-icon"></span>
            
  
    Demyelinating
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../ms-new-diagnosis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    MS New Diagnosis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../ms-chronic-management/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    MS Chronic Management
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_10" >
        
          
          <label class="md-nav__link" for="__nav_3_10" id="__nav_3_10_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Headache
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_10_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_10">
            <span class="md-nav__icon md-icon"></span>
            
  
    Headache
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../migraine/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Migraine
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../cluster-headache/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Cluster Headache
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../medication-overuse-headache/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Medication Overuse Headache
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_11" >
        
          
          <label class="md-nav__link" for="__nav_3_11" id="__nav_3_11_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Movement Disorders
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_11_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_11">
            <span class="md-nav__icon md-icon"></span>
            
  
    Movement Disorders
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../parkinsons-disease-new-diagnosis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Parkinson's Disease - New Diagnosis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../essential-tremor/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Essential Tremor
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../restless-legs-syndrome/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Restless Legs Syndrome
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_12" >
        
          
          <label class="md-nav__link" for="__nav_3_12" id="__nav_3_12_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Dementia & Cognitive
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_12_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_12">
            <span class="md-nav__icon md-icon"></span>
            
  
    Dementia & Cognitive
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../dementia-evaluation/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Dementia Evaluation
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../rapidly-progressive-dementia/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Rapidly Progressive Dementia
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_13" >
        
          
          <label class="md-nav__link" for="__nav_3_13" id="__nav_3_13_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Cranial Neuropathies
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_13_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_13">
            <span class="md-nav__icon md-icon"></span>
            
  
    Cranial Neuropathies
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../bells-palsy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Bell's Palsy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../trigeminal-neuralgia/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Trigeminal Neuralgia
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_14" >
        
          
          <label class="md-nav__link" for="__nav_3_14" id="__nav_3_14_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Intracranial Pressure
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_14_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_14">
            <span class="md-nav__icon md-icon"></span>
            
  
    Intracranial Pressure
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../idiopathic-intracranial-hypertension/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Idiopathic Intracranial Hypertension
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_15" >
        
          
          <label class="md-nav__link" for="__nav_3_15" id="__nav_3_15_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Metabolic & Nutritional
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_15_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_15">
            <span class="md-nav__icon md-icon"></span>
            
  
    Metabolic & Nutritional
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../wernicke-encephalopathy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Wernicke Encephalopathy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_16" >
        
          
          <label class="md-nav__link" for="__nav_3_16" id="__nav_3_16_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Syncope & Autonomic
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_16_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_16">
            <span class="md-nav__icon md-icon"></span>
            
  
    Syncope & Autonomic
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../syncope/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Syncope Evaluation
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_17" >
        
          
          <label class="md-nav__link" for="__nav_3_17" id="__nav_3_17_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Other
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_17_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_17">
            <span class="md-nav__icon md-icon"></span>
            
  
    Other
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../vertigo-dizziness-evaluation/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Vertigo / Dizziness
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
      
      
  
  
  
  
    
    
    
    
      
        
        
      
    
    
    <li class="md-nav__item md-nav__item--section md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_4" >
        
          
          <label class="md-nav__link" for="__nav_4" id="__nav_4_label" tabindex="">
            
  
  
  <span class="md-ellipsis">
    
  
    References
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_4_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_4">
            <span class="md-nav__icon md-icon"></span>
            
  
    References
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../references/lp-reference/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    LP Reference
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../references/tracker/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Template Tracker
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
    
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#1-laboratory-workup" class="md-nav__link">
    <span class="md-ellipsis">
      
        1. LABORATORY WORKUP
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#2-diagnostic-imaging-studies" class="md-nav__link">
    <span class="md-ellipsis">
      
        2. DIAGNOSTIC IMAGING &amp; STUDIES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#3-treatment" class="md-nav__link">
    <span class="md-ellipsis">
      
        3. TREATMENT
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#4-other-recommendations" class="md-nav__link">
    <span class="md-ellipsis">
      
        4. OTHER RECOMMENDATIONS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#5-differential-diagnosis" class="md-nav__link">
    <span class="md-ellipsis">
      
        5. DIFFERENTIAL DIAGNOSIS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#6-monitoring-parameters" class="md-nav__link">
    <span class="md-ellipsis">
      
        6. MONITORING PARAMETERS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#7-disposition-criteria" class="md-nav__link">
    <span class="md-ellipsis">
      
        7. DISPOSITION CRITERIA
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#8-evidence-references" class="md-nav__link">
    <span class="md-ellipsis">
      
        8. EVIDENCE &amp; REFERENCES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#change-log" class="md-nav__link">
    <span class="md-ellipsis">
      
        CHANGE LOG
      
    </span>
  </a>
  
</li>
      
    </ul>
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              
              <article class="md-content__inner md-typeset">
                
                  


  
  


<h1 id="myasthenia-gravis-new-diagnosis">Myasthenia Gravis - New Diagnosis<a class="headerlink" href="#myasthenia-gravis-new-diagnosis" title="Permanent link">&para;</a></h1>
<p><strong>VERSION:</strong> 1.0
<strong>CREATED:</strong> January 27, 2026
<strong>REVISED:</strong> January 27, 2026
<strong>STATUS:</strong> Initial creation</p>
<hr />
<p><strong>DIAGNOSIS:</strong> Myasthenia Gravis - New Diagnosis</p>
<p><strong>ICD-10:</strong> G70.0 (Myasthenia gravis), G70.00 (MG without exacerbation), G70.01 (MG with exacerbation)</p>
<p><strong>SYNONYMS:</strong> Myasthenia gravis, MG, new MG diagnosis, ocular myasthenia, generalized myasthenia, anti-AChR MG, anti-MuSK MG, seronegative MG, autoimmune neuromuscular junction disorder, fatigable weakness</p>
<p><strong>SCOPE:</strong> Initial diagnostic workup and management of suspected or newly confirmed myasthenia gravis. Covers antibody testing, electrodiagnostic studies, thymoma screening, acute stabilization, and long-term immunotherapy initiation. For myasthenic crisis with respiratory failure, use "Myasthenic Crisis" template. For established MG on maintenance therapy, use "MG - Maintenance" template.</p>
<hr />
<p><strong>PRIORITY KEY:</strong> STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>
<p>‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê
SECTION A: ACTION ITEMS
‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê</p>
<h2 id="1-laboratory-workup">1. LABORATORY WORKUP<a class="headerlink" href="#1-laboratory-workup" title="Permanent link">&para;</a></h2>
<h3 id="1a-essentialcore-labs">1A. Essential/Core Labs<a class="headerlink" href="#1a-essentialcore-labs" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Rationale</th>
<th>Target Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBC with differential</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Baseline before immunotherapy; infection screen</td>
<td>Normal</td>
</tr>
<tr>
<td>CMP</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Renal/hepatic function baseline; electrolytes</td>
<td>Normal</td>
</tr>
<tr>
<td>TSH</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Thyroid disease co-occurs in 10-15% of MG; autoimmune overlap</td>
<td>Normal</td>
</tr>
<tr>
<td>Free T4</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Thyroid function; Graves disease association</td>
<td>Normal</td>
</tr>
<tr>
<td>ESR</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Inflammatory/autoimmune screen</td>
<td>Normal (&lt;20 mm/hr)</td>
</tr>
<tr>
<td>CRP</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Inflammatory marker; infection screen</td>
<td>Normal</td>
</tr>
<tr>
<td>AChR binding antibody</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Primary diagnostic test; positive in ~85% generalized MG, ~50% ocular MG</td>
<td>Negative (&lt;0.02 nmol/L)</td>
</tr>
<tr>
<td>AChR blocking antibody</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Complements binding antibody; increases sensitivity</td>
<td>Negative</td>
</tr>
<tr>
<td>AChR modulating antibody</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Complements binding/blocking; increases sensitivity to ~95% in generalized MG</td>
<td>Negative</td>
</tr>
<tr>
<td>Blood glucose</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Pre-steroid baseline</td>
<td>Normal</td>
</tr>
<tr>
<td>HbA1c</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Glycemic status before corticosteroid initiation</td>
<td>&lt;5.7%</td>
</tr>
<tr>
<td>Urinalysis</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Infection screen; baseline</td>
<td>Negative</td>
</tr>
<tr>
<td>LDH</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Baseline; monitor for hemolysis on complement inhibitors</td>
<td>Normal</td>
</tr>
<tr>
<td>Magnesium</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Hypomagnesemia worsens NMJ transmission</td>
<td>Normal (1.7-2.2 mg/dL)</td>
</tr>
<tr>
<td>Phosphorus</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Baseline electrolyte panel</td>
<td>Normal</td>
</tr>
<tr>
<td>PT/INR</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Coagulation baseline before procedures</td>
<td>Normal</td>
</tr>
<tr>
<td>Hepatitis B surface antigen</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Screen before rituximab/immunosuppression (reactivation risk)</td>
<td>Negative</td>
</tr>
</tbody>
</table>
<h3 id="1b-extended-workup-second-line">1B. Extended Workup (Second-line)<a class="headerlink" href="#1b-extended-workup-second-line" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Rationale</th>
<th>Target Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>MuSK antibody (anti-MuSK IgG)</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Positive in ~40% of AChR-seronegative MG; distinct phenotype (bulbar, facial, neck weakness)</td>
<td>Negative</td>
</tr>
<tr>
<td>LRP4 antibody</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Positive in ~2-50% of double-seronegative MG; newer assay</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-striated muscle antibody (anti-SM)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Associated with thymoma in MG patients &lt;40 years; screening marker</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-titin antibody</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Associated with thymoma (especially in young-onset MG); late-onset MG marker</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-RyR (ryanodine receptor) antibody</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Associated with thymoma and severe MG</td>
<td>Negative</td>
</tr>
<tr>
<td>ANA</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Autoimmune overlap screen (SLE, Sjogren)</td>
<td>Negative or low titer</td>
</tr>
<tr>
<td>Anti-TPO antibody</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Autoimmune thyroiditis co-occurrence (Hashimoto/Graves)</td>
<td>Negative</td>
</tr>
<tr>
<td>Vitamin D (25-OH)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Immune modulation; deficiency common</td>
<td>&gt;30 ng/mL</td>
</tr>
<tr>
<td>Hepatitis B core antibody</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Screen for prior HBV before rituximab</td>
<td>Negative</td>
</tr>
<tr>
<td>Hepatitis C antibody</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Screen before immunosuppression</td>
<td>Negative</td>
</tr>
<tr>
<td>HIV</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Screen before immunosuppression</td>
<td>Negative</td>
</tr>
<tr>
<td>Quantitative immunoglobulins (IgG, IgA, IgM)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Baseline before IVIG; monitor on rituximab/immunosuppression</td>
<td>Normal</td>
</tr>
<tr>
<td>SPEP with immunofixation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Paraproteinemic neuropathy/NMJ screen in atypical cases</td>
<td>Normal</td>
</tr>
<tr>
<td>Complement C3, C4</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Baseline before complement inhibitor therapy</td>
<td>Normal</td>
</tr>
<tr>
<td>Reticulocyte count</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Baseline before complement inhibitors (hemolysis monitoring)</td>
<td>Normal</td>
</tr>
<tr>
<td>Haptoglobin</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Baseline for hemolysis monitoring on complement inhibitors</td>
<td>Normal</td>
</tr>
<tr>
<td>TB test (QuantiFERON-Gold or PPD)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Screen before immunosuppression</td>
<td>Negative</td>
</tr>
</tbody>
</table>
<h3 id="1c-rarespecialized-refractory-or-atypical">1C. Rare/Specialized (Refractory or Atypical)<a class="headerlink" href="#1c-rarespecialized-refractory-or-atypical" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Rationale</th>
<th>Target Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agrin antibody</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Novel antibody target in seronegative MG</td>
<td>Negative</td>
</tr>
<tr>
<td>Cortactin antibody</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Identified in some seronegative MG</td>
<td>Negative</td>
</tr>
<tr>
<td>ColQ antibody</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Congenital myasthenic syndrome screen</td>
<td>Negative</td>
</tr>
<tr>
<td>Genetic testing (CMS gene panel)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Congenital myasthenic syndromes (CHRNE, DOK7, RAPSN, etc.) if onset &lt;2 years or seronegative/atypical</td>
<td>Depends on gene</td>
</tr>
<tr>
<td>Paraneoplastic antibody panel (ANNA-1, VGCC, GAD65)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>LEMS or overlap paraneoplastic syndrome</td>
<td>Negative</td>
</tr>
<tr>
<td>VGCC antibody (P/Q-type)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Lambert-Eaton myasthenic syndrome screen</td>
<td>Negative (&lt;0.02 nmol/L)</td>
</tr>
<tr>
<td>SOX1 antibody</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Associated with SCLC in LEMS</td>
<td>Negative</td>
</tr>
<tr>
<td>Acetylcholine receptor ganglionic antibody</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Autonomic neuropathy overlap</td>
<td>Negative</td>
</tr>
<tr>
<td>Muscle biopsy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Myopathy screen if diagnosis unclear</td>
<td>Normal NMJ architecture</td>
</tr>
<tr>
<td>Anti-Kv1.4 antibody</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Associated with myocarditis and severe MG phenotype (Japan)</td>
<td>Negative</td>
</tr>
<tr>
<td>CT-guided thymoma biopsy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>If anterior mediastinal mass is atypical; tissue diagnosis</td>
<td>Depends on pathology</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="2-diagnostic-imaging-studies">2. DIAGNOSTIC IMAGING &amp; STUDIES<a class="headerlink" href="#2-diagnostic-imaging-studies" title="Permanent link">&para;</a></h2>
<h3 id="2a-essentialfirst-line">2A. Essential/First-line<a class="headerlink" href="#2a-essentialfirst-line" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT chest with contrast</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Within 24-48h of diagnosis</td>
<td>No thymoma or thymic hyperplasia</td>
<td>Contrast allergy, renal insufficiency</td>
</tr>
<tr>
<td>MRI chest with contrast (preferred over CT if available)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Within 1-2 weeks</td>
<td>No thymoma; thymic hyperplasia characterization</td>
<td>Gadolinium allergy, GFR &lt;30, pacemaker</td>
</tr>
<tr>
<td>Chest X-ray (PA and lateral)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Immediate</td>
<td>No mediastinal mass; baseline pulmonary status</td>
<td>None significant</td>
</tr>
<tr>
<td>Portable chest X-ray</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>If unable to go to radiology</td>
<td>Pulmonary status; mediastinal widening</td>
<td>None significant</td>
</tr>
</tbody>
</table>
<h3 id="2b-electrodiagnostic-specialized-studies">2B. Electrodiagnostic &amp; Specialized Studies<a class="headerlink" href="#2b-electrodiagnostic-specialized-studies" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repetitive nerve stimulation (RNS)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>During workup; stop pyridostigmine 12h prior if possible</td>
<td>Decremental response &gt;10% at 2-3 Hz in proximal and distal muscles</td>
<td>Pacemaker (relative); recent botulinum toxin</td>
</tr>
<tr>
<td>Single-fiber EMG (SFEMG)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>If RNS negative but clinical suspicion remains; most sensitive test (95-99%)</td>
<td>Increased jitter and blocking</td>
<td>Same as RNS; requires experienced electromyographer</td>
</tr>
<tr>
<td>Standard EMG/NCS</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>If diagnosis unclear; rule out neuropathy/myopathy</td>
<td>Normal (unless concurrent condition)</td>
<td>None significant</td>
</tr>
<tr>
<td>Ice pack test (ocular MG)</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>At bedside; apply ice to closed eyelid for 2 minutes</td>
<td>Improvement of ptosis by ‚â•2 mm (sensitivity ~80% for ocular MG)</td>
<td>Patient intolerance</td>
</tr>
<tr>
<td>Rest test (ocular MG)</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>At bedside; rest with eyes closed for 2-5 minutes</td>
<td>Improvement of ptosis or diplopia</td>
<td>None</td>
</tr>
<tr>
<td>Sleep test (ocular MG)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>At bedside; 30-minute nap then reassess</td>
<td>Improvement of ptosis/diplopia after rest</td>
<td>None</td>
</tr>
</tbody>
</table>
<h3 id="2c-bedside-clinical-tests">2C. Bedside Clinical Tests<a class="headerlink" href="#2c-bedside-clinical-tests" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sustained upgaze (2 minutes)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Initial exam</td>
<td>No fatigable ptosis</td>
<td>Positive = ptosis develops or worsens with sustained upgaze</td>
</tr>
<tr>
<td>Repeated deltoid abduction (15-20 reps)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Initial exam</td>
<td>No fatigable weakness</td>
<td>Positive = progressive weakness with repetitive testing</td>
</tr>
<tr>
<td>Cogan lid twitch sign</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Initial exam</td>
<td>No lid twitch</td>
<td>Have patient look down 15 sec, then look up: positive = brief upward overshoot of lid</td>
</tr>
<tr>
<td>Curtain sign (orbicularis oculi)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Initial exam</td>
<td>No contralateral lid opening</td>
<td>While examiner holds one ptotic lid open, the other droops further</td>
</tr>
<tr>
<td>Peek sign</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Initial exam</td>
<td>Sustained eye closure</td>
<td>Patient gently closes eyes for 30 sec: positive = sclera becomes visible (orbicularis weakness)</td>
</tr>
<tr>
<td>Forced vital capacity (FVC)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>At presentation and serially</td>
<td>&gt;20 mL/kg (&gt;1.5 L)</td>
<td>Critical: &lt;15 mL/kg or &lt;1 L = impending respiratory failure</td>
</tr>
<tr>
<td>Negative inspiratory force (NIF/MIP)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>At presentation and serially</td>
<td>More negative than -40 cm H2O</td>
<td>Critical: weaker than -20 cm H2O = consider intubation</td>
</tr>
</tbody>
</table>
<p><em>Note: Edrophonium (Tensilon) test rarely performed due to cardiac risks and availability issues; ice pack test preferred as bedside diagnostic.</em></p>
<hr />
<h2 id="3-treatment">3. TREATMENT<a class="headerlink" href="#3-treatment" title="Permanent link">&para;</a></h2>
<h3 id="3a-cholinesterase-inhibitors-symptomatic">3A. Cholinesterase Inhibitors (Symptomatic)<a class="headerlink" href="#3a-cholinesterase-inhibitors-symptomatic" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pyridostigmine (Mestinon) IR</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Start 30 mg TID; increase by 30 mg per dose every 2-3 days; usual effective dose 60 mg q4-6h while awake; max 120 mg per dose (max ~960 mg/day, rarely needed)</td>
<td>Mechanical GI/GU obstruction; uncontrolled asthma</td>
<td>Cholinergic side effects: diarrhea, cramping, salivation, bradycardia; cholinergic crisis if overdosed (weakness + muscarinic symptoms)</td>
</tr>
<tr>
<td>Pyridostigmine (Mestinon) SR (Timespan)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>180 mg qHS (sustained release); may give once or twice daily; do NOT crush</td>
<td>Same as IR</td>
<td>Same; useful for nocturnal/morning weakness; erratic absorption - use sparingly</td>
</tr>
<tr>
<td>Pyridostigmine liquid (60 mg/5 mL)</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Same dosing as IR; useful for patients with dysphagia</td>
<td>Same as IR</td>
<td>Same; easier to swallow</td>
</tr>
<tr>
<td>Neostigmine IV (if NPO or intubated)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td>0.5-2.5 mg IV/IM q1-3h; 1 mg IV neostigmine ‚âà 30 mg oral pyridostigmine</td>
<td>Same; cardiac monitoring required</td>
<td>Continuous cardiac monitoring; have atropine at bedside for bradycardia</td>
</tr>
<tr>
<td>Glycopyrrolate (for cholinergic side effects)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>1-2 mg PO BID-TID or 0.1-0.2 mg IV PRN</td>
<td>Narrow-angle glaucoma; obstructive uropathy</td>
<td>Does NOT cross BBB (preferred over atropine for peripheral muscarinic side effects)</td>
</tr>
<tr>
<td>Atropine (for cholinergic side effects/emergency)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>0.5-1 mg IV PRN for symptomatic bradycardia from pyridostigmine</td>
<td>Tachycardia; thyrotoxicosis</td>
<td>HR monitoring; crosses BBB (may cause confusion)</td>
</tr>
<tr>
<td>Pyridostigmine dose reduction/hold</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Hold or reduce if cholinergic crisis suspected (worsening weakness + excessive secretions)</td>
<td>N/A</td>
<td>Distinguish cholinergic crisis (excess pyridostigmine) from myasthenic crisis (undertreated MG)</td>
</tr>
</tbody>
</table>
<p><em>Note: MuSK-positive MG often responds poorly to pyridostigmine and may worsen; use cautiously and consider early immunotherapy.</em></p>
<h3 id="3b-corticosteroids-immunosuppression-induction">3B. Corticosteroids (Immunosuppression - Induction)<a class="headerlink" href="#3b-corticosteroids-immunosuppression-induction" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prednisone (gradual escalation - PREFERRED for outpatient)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Start 10-20 mg daily; increase by 5-10 mg every 3-5 days to target 0.5-1 mg/kg/day (typically 40-60 mg daily); maintain 4-8 weeks then taper by 5-10 mg/month</td>
<td>Active untreated infection; uncontrolled diabetes; psychosis history</td>
<td>Glucose (q6h inpatient, weekly outpatient); BP; mood/sleep; weight; bone density at baseline; GI prophylaxis</td>
</tr>
<tr>
<td>Prednisone (rapid escalation - INPATIENT preferred)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td>Start 40-60 mg daily (0.75-1 mg/kg/day); CAUTION: may cause initial transient worsening in first 1-2 weeks</td>
<td>Same as above</td>
<td>Same; MONITOR CLOSELY for steroid-induced exacerbation; consider concurrent IVIG/PLEX for protection</td>
</tr>
<tr>
<td>Methylprednisolone IV (pulse therapy)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>1000 mg IV daily √ó 3-5 days; transition to oral prednisone taper</td>
<td>Active untreated infection; uncontrolled diabetes; psychosis</td>
<td>Glucose q6h (target &lt;180); BP; mood; cardiac monitoring; GI prophylaxis</td>
</tr>
<tr>
<td>Omeprazole (GI prophylaxis during steroids)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>20-40 mg daily while on steroids</td>
<td>PPI allergy</td>
<td>None routine</td>
</tr>
<tr>
<td>Insulin sliding scale (steroid-induced hyperglycemia)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Per protocol if glucose &gt;180 mg/dL</td>
<td>Hypoglycemia risk</td>
<td>Glucose q6h</td>
</tr>
<tr>
<td>Calcium carbonate + Vitamin D (bone protection)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Calcium 1000-1200 mg + Vitamin D 1000-2000 IU daily while on chronic steroids</td>
<td>Hypercalcemia; hyperparathyroidism</td>
<td>Serum calcium; consider DEXA if anticipated steroid course &gt;3 months</td>
</tr>
<tr>
<td>Bisphosphonate (bone protection if chronic steroids)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Alendronate 70 mg PO weekly OR risedronate 35 mg PO weekly; start if steroids expected &gt;3 months</td>
<td>GFR &lt;35; esophageal disorders; inability to remain upright 30 min</td>
<td>DEXA at baseline; renal function; dental exam (ONJ risk)</td>
</tr>
<tr>
<td>Trimethoprim-sulfamethoxazole (PCP prophylaxis)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>1 DS tablet (160/800 mg) daily or 3 times per week if prednisone ‚â•20 mg for ‚â•4 weeks</td>
<td>Sulfonamide allergy; severe renal impairment</td>
<td>CBC; renal function; use dapsone or atovaquone if allergic</td>
</tr>
<tr>
<td>Prednisone taper</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Once stable on target dose for 4-8 weeks: decrease by 5-10 mg every 2-4 weeks until 20 mg, then decrease by 2.5-5 mg monthly; target lowest effective dose or off</td>
<td>Do NOT stop abruptly if &gt;2 weeks of therapy</td>
<td>Adrenal insufficiency symptoms; disease flare; cortisol level if concerns</td>
</tr>
</tbody>
</table>
<p><em>Note: Steroid-induced transient worsening occurs in ~50% of patients within first 2 weeks of high-dose initiation. Consider starting steroids in-hospital for patients with moderate-severe generalized MG or bulbar symptoms, or provide "bridge" therapy with IVIG/PLEX.</em></p>
<h3 id="3c-steroid-sparing-immunosuppressive-agents">3C. Steroid-Sparing Immunosuppressive Agents<a class="headerlink" href="#3c-steroid-sparing-immunosuppressive-agents" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mycophenolate mofetil (CellCept)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Start 500 mg BID; increase to 1000 mg BID after 2 weeks; target 2000-3000 mg/day in divided doses; onset 6-12 months</td>
<td>Pregnancy (Category D - teratogenic); concurrent azathioprine</td>
<td>CBC q2 weeks √ó 3 months, then monthly; LFTs; GI side effects (diarrhea, nausea); lymphopenia; REMS pregnancy prevention</td>
</tr>
<tr>
<td>Azathioprine (Imuran)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Start 50 mg daily; increase by 50 mg every 1-2 weeks to target 2-3 mg/kg/day (typically 150-250 mg/day); onset 6-18 months</td>
<td>TPMT deficiency (check before starting); concurrent allopurinol (reduce dose by 75%); pregnancy (relative)</td>
<td>TPMT genotype/activity BEFORE starting; CBC q1-2 weeks during titration, then monthly; LFTs; amylase/lipase if abdominal pain; lymphocyte count target 600-1000</td>
</tr>
<tr>
<td>Tacrolimus (Prograf)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Start 1 mg BID; titrate to trough level 5-10 ng/mL; onset 3-6 months (faster than MMF/AZA)</td>
<td>Uncontrolled hypertension; renal impairment</td>
<td>Trough levels; renal function q2 weeks then monthly; electrolytes (K, Mg); glucose; BP; tremor; nephrotoxicity</td>
</tr>
<tr>
<td>Cyclosporine (Sandimmune/Neoral)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Start 2-3 mg/kg/day in 2 divided doses; target trough 100-150 ng/mL; onset 2-6 months</td>
<td>Uncontrolled hypertension; renal impairment; concurrent nephrotoxic drugs</td>
<td>Trough levels; renal function; BP; electrolytes (K, Mg); lipids; gingival hyperplasia; hirsutism</td>
</tr>
<tr>
<td>Methotrexate</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>10-20 mg PO or SC once weekly with folic acid 1 mg daily (except methotrexate day); onset 6-12 months</td>
<td>Pregnancy (Category X); hepatic disease; renal impairment (CrCl &lt;30); concurrent trimethoprim</td>
<td>CBC q4 weeks; LFTs q8-12 weeks; renal function; pulmonary toxicity screen; folic acid supplementation mandatory</td>
</tr>
<tr>
<td>Cyclophosphamide (refractory/severe)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td>Pulse IV: 500-1000 mg/m¬≤ monthly √ó 6 months; OR oral 1-2 mg/kg/day; reserved for refractory MG</td>
<td>Pregnancy; active infection; bone marrow suppression</td>
<td>CBC weekly during treatment; urinalysis (hemorrhagic cystitis - MESNA with IV dosing); fertility counseling; malignancy risk</td>
</tr>
<tr>
<td>IVIG (maintenance immunomodulation)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td>1-2 g/kg divided over 2-5 days, then 0.4-1 g/kg every 4 weeks as maintenance</td>
<td>IgA deficiency (check IgA level first); recent thrombotic event; renal failure</td>
<td>Pre-infusion: IgA level, renal function, CBC; during: vital signs q15 min first hour; headache; aseptic meningitis; thrombosis risk; renal function</td>
</tr>
</tbody>
</table>
<h3 id="3d-biologics-complement-inhibitors-rescue-therapies">3D. Biologics, Complement Inhibitors &amp; Rescue Therapies<a class="headerlink" href="#3d-biologics-complement-inhibitors-rescue-therapies" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rituximab (Rituxan)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>375 mg/m¬≤ IV weekly √ó 4 weeks; OR 1000 mg IV √ó 2 doses 14 days apart; re-dose when CD19/CD20 recover or clinical worsening; onset 3-6 months</td>
<td>Active Hepatitis B; active infection; severe immunodeficiency</td>
<td>HBV serology before; CD19/CD20 counts q3-6 months; immunoglobulins q6 months; PML risk (very rare); infusion reactions (premedicate with acetaminophen, diphenhydramine, methylprednisolone)</td>
</tr>
<tr>
<td>Eculizumab (Soliris)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>900 mg IV weekly √ó 4 weeks, then 1200 mg IV at week 5, then 1200 mg IV every 2 weeks; for AChR-positive generalized MG</td>
<td>Unresolved Neisseria meningitidis infection; unvaccinated against meningococcus</td>
<td>Meningococcal vaccine ‚â•2 weeks before; REMS program; CBC; LDH/reticulocyte (hemolysis on discontinuation); signs of meningococcal infection; ciprofloxacin prophylaxis recommended</td>
</tr>
<tr>
<td>Ravulizumab (Ultomiris)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Weight-based loading dose IV, then maintenance every 8 weeks; for AChR-positive generalized MG</td>
<td>Same as eculizumab</td>
<td>Same as eculizumab; less frequent dosing advantage</td>
</tr>
<tr>
<td>Zilucoplan (Zilbrysq)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>0.3 mg/kg SC daily (self-administered); for AChR-positive generalized MG</td>
<td>Same as eculizumab</td>
<td>Same meningococcal vaccination required; injection site reactions; LDH; reticulocyte count</td>
</tr>
<tr>
<td>Efgartigimod (Vyvgart)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>10 mg/kg IV weekly √ó 4 weeks per cycle; may repeat based on clinical response; for AChR-positive generalized MG</td>
<td>Active infection; concurrent IgG-dependent therapies</td>
<td>IgG levels (expect ~70% reduction); infection monitoring; no meningococcal vaccine required</td>
</tr>
<tr>
<td>Efgartigimod/hyaluronidase SC (Vyvgart Hytrulo)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>1008 mg efgartigimod + 11,200 units hyaluronidase SC weekly √ó 4 weeks per cycle</td>
<td>Same as IV efgartigimod</td>
<td>Same; injection site reactions; self-administered option</td>
</tr>
<tr>
<td>Rozanolixizumab (Rystiggo)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Weight-based SC weekly √ó 6 weeks per cycle; for AChR-positive generalized MG</td>
<td>Active infection</td>
<td>IgG levels; headache common; pyrexia; infection monitoring</td>
</tr>
<tr>
<td>Plasmapheresis (PLEX) - rescue</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>5-7 exchanges over 10-14 days; exchange 1-1.5 plasma volumes per session</td>
<td>Hemodynamic instability; sepsis; line contraindication; heparin allergy</td>
<td>BP during exchange; electrolytes (Ca, K, Mg); coagulation studies; fibrinogen; line site infection; hypotension</td>
</tr>
<tr>
<td>IVIG (rescue therapy)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>2 g/kg divided over 2-5 days (e.g., 0.4 g/kg/day √ó 5 days)</td>
<td>IgA deficiency; renal failure; recent thrombotic event</td>
<td>Pre-infusion IgA level; renal function; vital signs; headache (aseptic meningitis); thrombosis risk</td>
</tr>
</tbody>
</table>
<p><em>Note: Complement inhibitors (eculizumab, ravulizumab, zilucoplan) and FcRn inhibitors (efgartigimod, rozanolixizumab) are FDA-approved for AChR antibody-positive generalized MG. They are NOT indicated for MuSK-positive or seronegative MG. Rituximab is first-line for MuSK-positive MG (excellent response rates).</em></p>
<h3 id="3e-surgical-treatment">3E. Surgical Treatment<a class="headerlink" href="#3e-surgical-treatment" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Indication</th>
<th>Contraindications</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thymectomy (VATS or robotic-assisted)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>AChR-positive generalized MG, age 18-65 (MGTX trial); any age with thymoma; consider in AChR-positive ocular MG with suboptimal response</td>
<td>MuSK-positive MG (no proven benefit); medically unstable; uncontrolled MG (optimize first)</td>
<td>MGTX trial: thymectomy + prednisone superior to prednisone alone at 3 years; optimize MG before surgery (FVC &gt;2L, no bulbar crisis); post-op ICU monitoring recommended</td>
</tr>
<tr>
<td>Thymectomy (median sternotomy)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td>Thymoma requiring complete resection; invasive thymoma</td>
<td>Same as above</td>
<td>More invasive; complete thymoma staging with Masaoka classification; consider neoadjuvant chemotherapy for advanced thymoma</td>
</tr>
<tr>
<td>Extended thymectomy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td>Thymoma with suspected extra-thymic extension</td>
<td>Same as above</td>
<td>Includes removal of all anterior mediastinal fat; en bloc resection</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="4-other-recommendations">4. OTHER RECOMMENDATIONS<a class="headerlink" href="#4-other-recommendations" title="Permanent link">&para;</a></h2>
<h3 id="4a-referrals-consults">4A. Referrals &amp; Consults<a class="headerlink" href="#4a-referrals-consults" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuromuscular specialist/MG specialist referral</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>All new MG diagnoses for treatment planning and long-term management</td>
</tr>
<tr>
<td>Thoracic surgery referral</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Thymoma present; AChR-positive generalized MG for thymectomy discussion</td>
</tr>
<tr>
<td>Pulmonology referral</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Respiratory compromise; pre-thymectomy pulmonary evaluation; chronic respiratory monitoring</td>
</tr>
<tr>
<td>Speech-language pathology (swallow evaluation)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Bulbar symptoms: dysphagia, dysarthria, nasal speech; aspiration risk</td>
</tr>
<tr>
<td>Occupational therapy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>ADL impairment; energy conservation; adaptive equipment</td>
</tr>
<tr>
<td>Physical therapy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td>Generalized weakness; deconditioning; fall prevention; exercise prescription</td>
</tr>
<tr>
<td>Ophthalmology/Neuro-ophthalmology</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Ocular MG; diplopia management; prism evaluation</td>
</tr>
<tr>
<td>Rheumatology referral</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Concurrent autoimmune disease (lupus, RA, thyroid disease)</td>
</tr>
<tr>
<td>Endocrinology referral</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Steroid-induced diabetes; thyroid disease management; osteoporosis</td>
</tr>
<tr>
<td>Psychiatry/Psychology referral</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Depression; anxiety; adjustment to chronic diagnosis; steroid-induced psychiatric symptoms</td>
</tr>
<tr>
<td>Social work consult</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Insurance navigation (biologic cost); disability evaluation; MG support resources</td>
</tr>
<tr>
<td>Respiratory therapy</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>FVC/NIF monitoring; ventilator management; BiPAP/CPAP evaluation</td>
</tr>
<tr>
<td>Nutrition/Dietetics</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Dysphagia diet modification; weight management on steroids; nutritional optimization</td>
</tr>
<tr>
<td>Anesthesiology consultation (pre-thymectomy)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Pre-operative assessment; avoidance of neuromuscular blocking agents; post-op ventilation planning</td>
</tr>
<tr>
<td>Infusion center coordination</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>IVIG scheduling; rituximab infusion; complement inhibitor infusions</td>
</tr>
<tr>
<td>Pain management referral</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Chronic pain from sustained muscle weakness or comorbid conditions</td>
</tr>
<tr>
<td>Palliative care (refractory cases)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Severely refractory MG with significant symptom burden; goals of care discussion</td>
</tr>
<tr>
<td>MG Foundation / Patient advocacy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Patient support groups; educational materials; myasthenia.org referral</td>
</tr>
</tbody>
</table>
<h3 id="4b-patient-instructions">4B. Patient Instructions<a class="headerlink" href="#4b-patient-instructions" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Return to ED immediately if difficulty breathing, swallowing, or speaking</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
</tr>
<tr>
<td>Return to ED if new severe weakness, double vision worsening acutely, or unable to hold head up</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
</tr>
<tr>
<td>Take pyridostigmine 30-60 minutes BEFORE meals to help with chewing and swallowing</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
</tr>
<tr>
<td>Do NOT take pyridostigmine more frequently than prescribed (cholinergic crisis risk)</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
</tr>
<tr>
<td>Report excessive salivation, diarrhea, cramping, or muscle twitching (cholinergic side effects)</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
</tr>
<tr>
<td>Carry MG medical alert identification at all times</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
</tr>
<tr>
<td>Provide MG medication list to ALL healthcare providers (emergency, dental, surgical)</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
</tr>
<tr>
<td>Avoid extreme heat, hot baths/saunas (may worsen weakness)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
</tr>
<tr>
<td>Plan activities for times of best strength (usually morning after pyridostigmine)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
</tr>
<tr>
<td>Rest before meals if dysphagia present; eat smaller, more frequent meals</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
</tr>
<tr>
<td>Do NOT stop prednisone or immunosuppressant abruptly (adrenal crisis/flare risk)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
</tr>
<tr>
<td>Avoid alcohol (potentiates weakness and interacts with medications)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
</tr>
<tr>
<td>Report any signs of infection immediately (fever, cough, dysuria) especially if on immunosuppression</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
</tr>
<tr>
<td>Contact neurologist before taking any new medications (many drugs worsen MG)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
</tr>
<tr>
<td>Do NOT use over-the-counter magnesium-containing products without physician approval</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
</tr>
<tr>
<td>Keep emergency contact numbers for MG specialist readily available</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
</tr>
<tr>
<td>Understand the difference between myasthenic crisis and cholinergic crisis</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
</tr>
<tr>
<td>Monitor and report progressive difficulty climbing stairs, rising from chairs, or lifting arms above head</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
</tr>
</tbody>
</table>
<h3 id="4c-medications-to-avoid-in-myasthenia-gravis">4C. Medications to Avoid in Myasthenia Gravis<a class="headerlink" href="#4c-medications-to-avoid-in-myasthenia-gravis" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Medication/Class</th>
<th style="text-align: center;">Risk Level</th>
<th>Details</th>
<th>Safe Alternative (if applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANTIBIOTICS</strong></td>
<td style="text-align: center;"></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aminoglycosides (gentamicin, tobramycin, amikacin, streptomycin)</td>
<td style="text-align: center;">HIGH</td>
<td>Impair presynaptic ACh release AND postsynaptic receptor function; can precipitate crisis</td>
<td>Use non-aminoglycoside antibiotics based on culture sensitivity</td>
</tr>
<tr>
<td>Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin)</td>
<td style="text-align: center;">HIGH</td>
<td>NMJ blocking effect; FDA black box warning for MG exacerbation</td>
<td>Beta-lactams, cephalosporins (generally safe)</td>
</tr>
<tr>
<td>Macrolides (azithromycin, erythromycin, clarithromycin)</td>
<td style="text-align: center;">MODERATE</td>
<td>Reports of MG worsening; telithromycin (CONTRAINDICATED - fatal cases)</td>
<td>Penicillins, cephalosporins</td>
</tr>
<tr>
<td>Tetracyclines (doxycycline, minocycline)</td>
<td style="text-align: center;">LOW-MODERATE</td>
<td>Rare reports of worsening; use with caution</td>
<td>Amoxicillin for common infections</td>
</tr>
<tr>
<td>Polymyxins (colistin)</td>
<td style="text-align: center;">HIGH</td>
<td>Strong NMJ blocking effect</td>
<td>Alternative per culture sensitivity</td>
</tr>
<tr>
<td><strong>CARDIOVASCULAR</strong></td>
<td style="text-align: center;"></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta-blockers (propranolol, metoprolol, atenolol)</td>
<td style="text-align: center;">MODERATE</td>
<td>May worsen weakness; impair NMJ transmission</td>
<td>ACE inhibitors, ARBs, CCBs (amlodipine)</td>
</tr>
<tr>
<td>Calcium channel blockers (verapamil, diltiazem)</td>
<td style="text-align: center;">MODERATE</td>
<td>Impair presynaptic calcium-dependent ACh release</td>
<td>Amlodipine (lower risk); ACE inhibitors</td>
</tr>
<tr>
<td>Procainamide</td>
<td style="text-align: center;">HIGH</td>
<td>NMJ blocking effect; may induce MG antibodies</td>
<td>Amiodarone (use cautiously)</td>
</tr>
<tr>
<td>Quinidine</td>
<td style="text-align: center;">HIGH</td>
<td>NMJ blocking effect; can precipitate crisis</td>
<td>Consult cardiology for alternatives</td>
</tr>
<tr>
<td>Lidocaine (IV)</td>
<td style="text-align: center;">MODERATE</td>
<td>High-dose IV may worsen NMJ transmission</td>
<td>Local/low-dose generally safe</td>
</tr>
<tr>
<td>Magnesium sulfate IV</td>
<td style="text-align: center;">HIGH</td>
<td>Inhibits presynaptic ACh release; can precipitate crisis</td>
<td>Avoid except life-threatening hypomagnesemia or eclampsia; ICU monitoring required</td>
</tr>
<tr>
<td><strong>NEUROPSYCHIATRIC</strong></td>
<td style="text-align: center;"></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D-penicillamine</td>
<td style="text-align: center;">HIGH</td>
<td>Can induce MG autoantibodies; CONTRAINDICATED</td>
<td>Trientine for Wilson disease</td>
</tr>
<tr>
<td>Phenytoin</td>
<td style="text-align: center;">MODERATE</td>
<td>May worsen NMJ transmission; case reports of MG exacerbation</td>
<td>Levetiracetam, lacosamide, valproate</td>
</tr>
<tr>
<td>Botulinum toxin</td>
<td style="text-align: center;">HIGH</td>
<td>Blocks presynaptic ACh release; CONTRAINDICATED in MG (systemic weakness risk)</td>
<td>Physical therapy; oral medications</td>
</tr>
<tr>
<td>Chlorpromazine, haloperidol</td>
<td style="text-align: center;">MODERATE</td>
<td>Reports of MG worsening</td>
<td>Atypical antipsychotics (quetiapine - use cautiously)</td>
</tr>
<tr>
<td>Lithium</td>
<td style="text-align: center;">MODERATE</td>
<td>May worsen NMJ transmission</td>
<td>Valproate, lamotrigine for mood stabilization</td>
</tr>
<tr>
<td>Benzodiazepines (high dose)</td>
<td style="text-align: center;">MODERATE</td>
<td>Respiratory depression; muscle relaxation compounds weakness</td>
<td>Low-dose short-acting with monitoring; melatonin for insomnia</td>
</tr>
<tr>
<td><strong>ANESTHETIC/SURGICAL</strong></td>
<td style="text-align: center;"></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Succinylcholine</td>
<td style="text-align: center;">HIGH</td>
<td>Unpredictable response: resistance (need higher dose) in chronic MG; prolonged block risk</td>
<td>Non-depolarizing agents at reduced dose with monitoring (rocuronium with sugammadex reversal)</td>
</tr>
<tr>
<td>Non-depolarizing NM blockers (vecuronium, pancuronium, rocuronium)</td>
<td style="text-align: center;">HIGH</td>
<td>Exaggerated and prolonged response; use 1/3 to 1/2 normal dose if necessary</td>
<td>Sugammadex for reversal of rocuronium; monitor with TOF</td>
</tr>
<tr>
<td>Volatile anesthetics (isoflurane, sevoflurane, desflurane)</td>
<td style="text-align: center;">MODERATE</td>
<td>May potentiate NMJ blockade; use reduced doses</td>
<td>TIVA (total intravenous anesthesia) considered safer</td>
</tr>
<tr>
<td><strong>IMMUNE/CHECKPOINT</strong></td>
<td style="text-align: center;"></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immune checkpoint inhibitors (nivolumab, pembrolizumab, ipilimumab)</td>
<td style="text-align: center;">HIGH</td>
<td>Can trigger de novo MG or cause fatal exacerbation of pre-existing MG</td>
<td>CONTRAINDICATED in known MG; if must use for malignancy, extreme caution with close monitoring</td>
</tr>
<tr>
<td>Interferon-alpha</td>
<td style="text-align: center;">MODERATE</td>
<td>Can unmask or worsen autoimmune MG</td>
<td>Avoid if possible</td>
</tr>
<tr>
<td><strong>OTHER</strong></td>
<td style="text-align: center;"></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quinine/tonic water</td>
<td style="text-align: center;">MODERATE</td>
<td>NMJ blocking effect</td>
<td>Avoid quinine-containing beverages</td>
</tr>
<tr>
<td>Statins (atorvastatin, simvastatin, rosuvastatin)</td>
<td style="text-align: center;">LOW</td>
<td>Rare myopathy; rare MG exacerbation reports; generally safe with monitoring</td>
<td>Continue if indicated; monitor for worsening</td>
</tr>
<tr>
<td>Iodinated contrast agents</td>
<td style="text-align: center;">LOW</td>
<td>Rare reports of transient worsening</td>
<td>Use with monitoring; pre-hydrate</td>
</tr>
<tr>
<td>Penicillamine</td>
<td style="text-align: center;">HIGH</td>
<td>Induces autoimmune MG; CONTRAINDICATED</td>
<td>Trientine</td>
</tr>
</tbody>
</table>
<p><em>Note: This list is not exhaustive. ALWAYS check individual medications for MG safety before prescribing. When in doubt, consult neuromuscular specialist or pharmacist. Many drugs have case reports of MG exacerbation - use clinical judgment.</em></p>
<h3 id="4d-vaccinations">4D. Vaccinations<a class="headerlink" href="#4d-vaccinations" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meningococcal ACWY vaccine (Menactra or MenQuadfi)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>REQUIRED ‚â•2 weeks before complement inhibitor therapy (eculizumab, ravulizumab, zilucoplan)</td>
</tr>
<tr>
<td>Meningococcal B vaccine (Bexsero or Trumenba)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>REQUIRED ‚â•2 weeks before complement inhibitor therapy; 2-dose series</td>
</tr>
<tr>
<td>Influenza vaccine (inactivated)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Annually; safe in MG; use inactivated form (not live nasal spray)</td>
</tr>
<tr>
<td>Pneumococcal vaccines (PCV20 or PCV15 + PPSV23)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Recommended before immunosuppression; per CDC schedule</td>
</tr>
<tr>
<td>COVID-19 vaccine (mRNA)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Recommended; rare reports of MG flare but benefits outweigh risks; monitor 2-4 weeks post-vaccination</td>
</tr>
<tr>
<td>Hepatitis B vaccine</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>If seronegative and starting rituximab/immunosuppression</td>
</tr>
<tr>
<td>Shingles vaccine (Shingrix - recombinant, non-live)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Age ‚â•50 or immunosuppressed; Shingrix is NOT a live vaccine (safe on immunosuppression)</td>
</tr>
<tr>
<td>AVOID all LIVE vaccines during immunosuppression</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">-</td>
<td>No MMR, varicella, live zoster (Zostavax), live influenza (FluMist), yellow fever, oral typhoid while on immunosuppressive therapy</td>
</tr>
<tr>
<td>Complete vaccinations BEFORE starting immunosuppression when possible</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">-</td>
<td>Ideally 4-6 weeks before rituximab, mycophenolate, or other immunosuppressants</td>
</tr>
<tr>
<td>VZV IgG titer (check before immunosuppression)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>If non-immune: vaccinate with Varivax (live) before starting immunosuppression; wait 4 weeks after vaccination</td>
</tr>
</tbody>
</table>
<h3 id="4e-pregnancy-considerations">4E. Pregnancy Considerations<a class="headerlink" href="#4e-pregnancy-considerations" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>MG course in pregnancy is unpredictable: 1/3 improve, 1/3 worsen, 1/3 unchanged</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td>Highest risk of exacerbation in first trimester and postpartum</td>
</tr>
<tr>
<td>Pyridostigmine is safe in pregnancy (Category B equivalent)</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td>Continue as needed; IV neostigmine safe in labor</td>
</tr>
<tr>
<td>Prednisone is relatively safe in pregnancy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">-</td>
<td>Use lowest effective dose; monitor for gestational diabetes; prednisone preferred (metabolized by placenta)</td>
</tr>
<tr>
<td>Azathioprine may be continued in pregnancy if necessary</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">-</td>
<td>Benefits may outweigh risks; discuss with maternal-fetal medicine</td>
</tr>
<tr>
<td>Mycophenolate is CONTRAINDICATED in pregnancy (Category D/X)</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td>Teratogenic; must be stopped ‚â•6 weeks before conception; REMS pregnancy prevention program</td>
</tr>
<tr>
<td>Methotrexate is CONTRAINDICATED in pregnancy (Category X)</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td>Teratogenic/abortifacient; stop ‚â•3 months before conception</td>
</tr>
<tr>
<td>Rituximab: stop ‚â•12 months before conception</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">-</td>
<td>B-cell depletion risk to neonate; limited data</td>
</tr>
<tr>
<td>Complement/FcRn inhibitors: insufficient pregnancy data</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">-</td>
<td>Discuss risks/benefits with MG specialist and MFM</td>
</tr>
<tr>
<td>IVIG is safe in pregnancy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td>Preferred rescue therapy if needed during pregnancy</td>
</tr>
<tr>
<td>PLEX is safe in pregnancy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td>Preferred rescue therapy; monitor for hypotension</td>
</tr>
<tr>
<td>Monitor neonate for transient neonatal MG</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td>Occurs in 10-20% of babies born to MG mothers; maternal AChR antibodies cross placenta; self-limited (resolves within weeks); NICU alert</td>
</tr>
<tr>
<td>Avoid magnesium sulfate for eclampsia in MG</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td>Magnesium blocks NMJ; may precipitate crisis; use alternative tocolytics/anticonvulsants (levetiracetam)</td>
</tr>
<tr>
<td>Breastfeeding generally safe on pyridostigmine and prednisone</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">-</td>
<td>Avoid breastfeeding on mycophenolate, methotrexate, cyclophosphamide</td>
</tr>
<tr>
<td>Plan delivery at facility with NICU and neurology support</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">-</td>
<td>Vaginal delivery preferred; cesarean only for obstetric indications; regional anesthesia preferred over general</td>
</tr>
<tr>
<td>Maternal-fetal medicine co-management for all MG pregnancies</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">‚úì</td>
<td style="text-align: center;">-</td>
<td>Pre-conception counseling recommended; multidisciplinary approach</td>
</tr>
</tbody>
</table>
<hr />
<p>‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê
SECTION B: REFERENCE (Expand as Needed)
‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê</p>
<h2 id="5-differential-diagnosis">5. DIFFERENTIAL DIAGNOSIS<a class="headerlink" href="#5-differential-diagnosis" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>Alternative Diagnosis</th>
<th>Key Distinguishing Features</th>
<th>Tests to Differentiate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lambert-Eaton Myasthenic Syndrome (LEMS)</td>
<td>Proximal weakness with improvement after exertion (facilitation); autonomic dysfunction; dry mouth; associated with SCLC; depressed reflexes that improve post-exercise</td>
<td>VGCC antibody (P/Q-type); incremental response on RNS at 50 Hz; CT chest for malignancy</td>
</tr>
<tr>
<td>Botulism</td>
<td>Acute onset descending paralysis; dilated/fixed pupils; recent ingestion of canned food or wound; autonomic dysfunction; no prior NMJ disease</td>
<td>Stool/serum botulinum toxin assay; EMG: BSAP pattern; incremental response on high-frequency RNS</td>
</tr>
<tr>
<td>Congenital Myasthenic Syndromes (CMS)</td>
<td>Childhood onset; family history; seronegative; variable inheritance patterns; specific gene mutations</td>
<td>Genetic testing (CMS gene panel: CHRNE, DOK7, RAPSN, CHAT, COLQ); no autoantibodies</td>
</tr>
<tr>
<td>Thyroid ophthalmopathy (Graves)</td>
<td>Proptosis; restrictive (not fatigable) diplopia; lid lag; thyroid dysfunction; MRI shows enlarged EOMs</td>
<td>TSH, free T4, TSI, orbital MRI showing EOM enlargement (not NMJ issue)</td>
</tr>
<tr>
<td>Progressive external ophthalmoplegia (PEO)</td>
<td>Slowly progressive bilateral ptosis and ophthalmoparesis; non-fatigable; no diurnal variation; may have pigmentary retinopathy</td>
<td>Muscle biopsy (ragged red fibers, COX-negative); mitochondrial DNA analysis</td>
</tr>
<tr>
<td>Oculopharyngeal muscular dystrophy (OPMD)</td>
<td>Late-onset (&gt;40) progressive ptosis and dysphagia; autosomal dominant; no fatigability; specific ethnic prevalence (French-Canadian, Bukharan Jewish)</td>
<td>Genetic testing (PABPN1 gene, GCN trinucleotide repeat); CK may be mildly elevated</td>
</tr>
<tr>
<td>Motor neuron disease (ALS/PBP)</td>
<td>Progressive weakness without fatigability; fasciculations; UMN signs (hyperreflexia, Babinski); no sensory loss; bulbar onset may mimic MG</td>
<td>EMG/NCS: active denervation, fasciculations; normal RNS; no antibodies</td>
</tr>
<tr>
<td>Inflammatory myopathy (PM/DM/IBM)</td>
<td>Proximal weakness without fatigability; elevated CK; skin findings in DM; no ptosis/diplopia (usually); IBM with grip/quad weakness</td>
<td>CK; myositis antibody panel; EMG: myopathic pattern; muscle biopsy</td>
</tr>
<tr>
<td>Brainstem stroke</td>
<td>Acute onset; cranial nerve palsies without fatigability; other focal neurological signs; vascular risk factors</td>
<td>Brain MRI with DWI; MRA; CTA</td>
</tr>
<tr>
<td>Miller Fisher syndrome (GBS variant)</td>
<td>Acute ophthalmoplegia, ataxia, areflexia; post-infectious; no fatigability</td>
<td>Anti-GQ1b antibody; CSF albuminocytologic dissociation; NCS (reduced SNAPs)</td>
</tr>
<tr>
<td>Myotonic dystrophy</td>
<td>Ptosis and facial weakness; myotonia (delayed relaxation); distal &gt; proximal weakness; cataracts; cardiac conduction abnormalities</td>
<td>Genetic testing (DMPK CTG repeat for DM1, CNBP CCTG repeat for DM2); EMG: myotonic discharges</td>
</tr>
<tr>
<td>Chronic inflammatory demyelinating polyneuropathy (CIDP)</td>
<td>Progressive proximal and distal weakness; hyporeflexia/areflexia; sensory involvement; elevated CSF protein</td>
<td>NCS: demyelinating pattern; CSF protein; nerve biopsy</td>
</tr>
<tr>
<td>Sarcoidosis (neuromuscular)</td>
<td>Granulomatous myopathy or cranial neuropathy; systemic involvement (lungs, skin, eyes); elevated ACE</td>
<td>ACE level; chest CT; biopsy (non-caseating granulomas); gallium scan</td>
</tr>
<tr>
<td>Drug-induced MG</td>
<td>Temporal correlation with offending drug (D-penicillamine, checkpoint inhibitors, statins); antibodies may be present</td>
<td>Drug history; antibody testing; improvement after drug withdrawal</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="6-monitoring-parameters">6. MONITORING PARAMETERS<a class="headerlink" href="#6-monitoring-parameters" title="Permanent link">&para;</a></h2>
<h3 id="6a-acute-monitoring-ed-inpatient-icu">6A. Acute Monitoring (ED / Inpatient / ICU)<a class="headerlink" href="#6a-acute-monitoring-ed-inpatient-icu" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Frequency</th>
<th>Target/Threshold</th>
<th>Action if Abnormal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Forced vital capacity (FVC)</td>
<td>Q4-6h in acute; Q shift if stable</td>
<td>&gt;20 mL/kg (&gt;1.5 L)</td>
<td>If &lt;15 mL/kg or &lt;1 L: impending respiratory failure, prepare for intubation; ICU transfer</td>
</tr>
<tr>
<td>Negative inspiratory force (NIF/MIP)</td>
<td>Q4-6h in acute; Q shift if stable</td>
<td>More negative than -40 cm H2O</td>
<td>If weaker than -20 cm H2O: intubate; -20 to -30 = ICU monitoring</td>
</tr>
<tr>
<td>Peak expiratory flow (PEF)</td>
<td>Q4-6h in acute</td>
<td>&gt;200 L/min</td>
<td>Declining PEF = weakening respiratory muscles</td>
</tr>
<tr>
<td>Oxygen saturation (SpO2)</td>
<td>Continuous in acute</td>
<td>&gt;94%</td>
<td>Supplemental O2; BiPAP; intubation if declining</td>
</tr>
<tr>
<td>Swallow function assessment</td>
<td>Daily; each meal if bulbar symptoms</td>
<td>Safe oral intake</td>
<td>NPO if aspiration risk; NG tube or modified diet; SLP consult</td>
</tr>
<tr>
<td>Neurologic exam (MG-specific)</td>
<td>Q shift inpatient; BID in ICU</td>
<td>Stable or improving strength</td>
<td>If worsening: reassess pyridostigmine dose; consider IVIG/PLEX; check for cholinergic crisis</td>
</tr>
<tr>
<td>Blood glucose</td>
<td>Q6h during IV/high-dose steroids</td>
<td>&lt;180 mg/dL</td>
<td>Insulin sliding scale; endocrine consult if persistent &gt;250</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>Q shift during steroids</td>
<td>&lt;160/100 mmHg</td>
<td>Antihypertensives PRN</td>
</tr>
<tr>
<td>Temperature</td>
<td>Q shift</td>
<td>Afebrile</td>
<td>Infection workup if febrile (infection is leading MG crisis trigger)</td>
</tr>
<tr>
<td>Electrolytes (K, Mg, Ca, Phos)</td>
<td>Daily while acute</td>
<td>Normal ranges</td>
<td>Replace aggressively; hypokalemia and hypomagnesemia worsen NMJ transmission</td>
</tr>
<tr>
<td>I/O and daily weight</td>
<td>Daily (inpatient)</td>
<td>Euvolemic</td>
<td>Adjust fluids; diuretics if overload</td>
</tr>
<tr>
<td>Cardiac monitoring</td>
<td>Continuous if on neostigmine IV; during PLEX</td>
<td>Normal rhythm</td>
<td>Atropine for bradycardia; PLEX can cause electrolyte-mediated arrhythmias</td>
</tr>
<tr>
<td>Mood and sleep assessment</td>
<td>Daily during steroids</td>
<td>No psychosis, mania, severe insomnia</td>
<td>Psychiatry consult; consider dose adjustment</td>
</tr>
<tr>
<td>Aspiration precautions</td>
<td>Throughout admission if bulbar symptoms</td>
<td>No aspiration events</td>
<td>HOB elevated; thickened liquids; SLP-guided diet</td>
</tr>
</tbody>
</table>
<h3 id="6b-chronicoutpatient-monitoring">6B. Chronic/Outpatient Monitoring<a class="headerlink" href="#6b-chronicoutpatient-monitoring" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Frequency</th>
<th>Target/Threshold</th>
<th>Action if Abnormal</th>
</tr>
</thead>
<tbody>
<tr>
<td>MG-ADL score</td>
<td>Each clinic visit</td>
<td>Minimal symptom score (goal &lt;6)</td>
<td>Escalate therapy if increasing; assess adherence</td>
</tr>
<tr>
<td>QMG score (Quantitative MG Score)</td>
<td>Each clinic visit or q3 months</td>
<td>Improvement ‚â•3.5 points = clinically meaningful</td>
<td>Treatment escalation if not meeting goals</td>
</tr>
<tr>
<td>FVC (office spirometry)</td>
<td>Each visit initially; q3-6 months when stable</td>
<td>&gt;80% predicted</td>
<td>Pulmonology referral if declining; assess respiratory muscle involvement</td>
</tr>
<tr>
<td>CBC with differential</td>
<td>Q2-4 weeks during AZA/MMF titration; then q3 months</td>
<td>WBC &gt;3000; ANC &gt;1500; lymphocytes 600-1000 (on AZA)</td>
<td>Hold/reduce immunosuppressant if cytopenic; G-CSF if severe neutropenia</td>
</tr>
<tr>
<td>LFTs</td>
<td>Q2-4 weeks during AZA/MMF/MTX titration; then q3 months</td>
<td>AST/ALT &lt;3√ó ULN</td>
<td>Reduce or hold offending agent; hepatology referral if persistent</td>
</tr>
<tr>
<td>Renal function (BUN/Cr)</td>
<td>Q3 months on tacrolimus/cyclosporine; q6 months otherwise</td>
<td>Normal eGFR</td>
<td>Dose adjustment; avoid nephrotoxins</td>
</tr>
<tr>
<td>Fasting glucose / HbA1c</td>
<td>Q3 months while on steroids</td>
<td>HbA1c &lt;7%</td>
<td>Endocrinology referral; steroid dose reduction; oral hypoglycemic or insulin</td>
</tr>
<tr>
<td>DEXA scan (bone density)</td>
<td>Baseline if starting chronic steroids; repeat q2 years</td>
<td>T-score &gt; -1.0</td>
<td>Bisphosphonate; calcium/vitamin D; endocrinology referral</td>
</tr>
<tr>
<td>Ophthalmologic exam</td>
<td>Annually if on chronic steroids; q6 months first year on steroids</td>
<td>No cataracts or glaucoma</td>
<td>Ophthalmology referral for cataracts (steroid-induced); IOP monitoring</td>
</tr>
<tr>
<td>CD19/CD20 B-cell counts (if on rituximab)</td>
<td>Q3-6 months</td>
<td>Depleted B-cells (therapeutic); monitor for recovery</td>
<td>Redose rituximab when B-cells recover and symptoms worsen</td>
</tr>
<tr>
<td>Immunoglobulin levels (IgG, IgA, IgM)</td>
<td>Q6 months if on rituximab/chronic immunosuppression</td>
<td>IgG &gt;400 mg/dL</td>
<td>IVIG replacement if symptomatic hypogammaglobulinemia with recurrent infections</td>
</tr>
<tr>
<td>IgG level (if on FcRn inhibitor)</td>
<td>Before each treatment cycle</td>
<td>~70% reduction expected during treatment</td>
<td>Guide retreatment timing; monitor for infection</td>
</tr>
<tr>
<td>Tacrolimus/cyclosporine trough level</td>
<td>Q1-2 weeks during titration; then q1-3 months</td>
<td>Tacrolimus 5-10 ng/mL; cyclosporine 100-150 ng/mL</td>
<td>Dose adjustment based on level and clinical response</td>
</tr>
<tr>
<td>CT chest (thymoma surveillance)</td>
<td>Annually √ó 5 years after thymectomy for thymoma; if not resected: q6-12 months</td>
<td>No recurrence or growth</td>
<td>Thoracic surgery referral for recurrence; consider radiation/chemotherapy</td>
</tr>
<tr>
<td>LDH, reticulocyte count, haptoglobin (if on complement inhibitor)</td>
<td>Q2-4 weeks initially; then q3 months</td>
<td>No hemolysis</td>
<td>If discontinuing complement inhibitor: monitor closely for rebound hemolysis</td>
</tr>
<tr>
<td>Meningococcal infection surveillance (if on complement inhibitor)</td>
<td>Each visit; patient education</td>
<td>No signs of meningococcal disease</td>
<td>Emergency evaluation for fever, headache, neck stiffness, rash; ensure vaccination current; ciprofloxacin prophylaxis</td>
</tr>
<tr>
<td>Vitamin D level</td>
<td>Annually</td>
<td>&gt;30 ng/mL</td>
<td>Supplement 2000-5000 IU daily</td>
</tr>
<tr>
<td>Thyroid function (TSH)</td>
<td>Annually (autoimmune overlap)</td>
<td>Normal</td>
<td>Endocrinology referral if abnormal</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="7-disposition-criteria">7. DISPOSITION CRITERIA<a class="headerlink" href="#7-disposition-criteria" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>Disposition</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Discharge home</strong></td>
<td>Mild symptoms (ocular only or mild generalized); FVC &gt;60% predicted and stable; adequate oral intake; pyridostigmine optimized; reliable follow-up within 1-2 weeks; understands return precautions; crisis action plan reviewed</td>
</tr>
<tr>
<td><strong>Admit to floor (general neurology)</strong></td>
<td>Moderate generalized weakness; FVC 40-60% predicted and stable; dysphagia requiring diet modification but tolerating PO; new diagnosis requiring expedited workup; steroid initiation with concern for transient worsening; IVIG infusion</td>
</tr>
<tr>
<td><strong>Admit to step-down/telemetry</strong></td>
<td>FVC 30-40% predicted or declining trend; moderate bulbar symptoms; starting PLEX; significant comorbidities requiring closer monitoring; recent cholinergic vs myasthenic crisis distinction unclear</td>
</tr>
<tr>
<td><strong>Admit to ICU</strong></td>
<td>FVC &lt;30% predicted or &lt;1 L; NIF weaker than -25 cm H2O; progressive respiratory failure; impending intubation; active myasthenic crisis; severe bulbar dysfunction with aspiration; hemodynamic instability during PLEX</td>
</tr>
<tr>
<td><strong>Transfer to higher level</strong></td>
<td>PLEX needed but unavailable; neuromuscular specialist not available; ICU capability needed but not present; thymectomy needed at specialized center</td>
</tr>
<tr>
<td><strong>Discharge from hospital</strong></td>
<td>FVC &gt;50% predicted and improving; adequate oral intake; stable on oral medications; immunotherapy plan established; outpatient follow-up scheduled within 1-2 weeks; patient and family educated on crisis recognition</td>
</tr>
</tbody>
</table>
<h3 id="mgfa-clinical-classification">MGFA Clinical Classification<a class="headerlink" href="#mgfa-clinical-classification" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class I</strong></td>
<td>Any ocular muscle weakness; may have weakness of eye closure; all other muscle strength is normal</td>
</tr>
<tr>
<td><strong>Class II</strong></td>
<td>Mild weakness affecting muscles other than ocular; may also have ocular weakness of any severity</td>
</tr>
<tr>
<td><strong>Class IIa</strong></td>
<td>Predominantly affecting limb, axial muscles, or both; may also have lesser involvement of oropharyngeal muscles</td>
</tr>
<tr>
<td><strong>Class IIb</strong></td>
<td>Predominantly affecting oropharyngeal, respiratory muscles, or both; may also have lesser or equal involvement of limb, axial muscles, or both</td>
</tr>
<tr>
<td><strong>Class III</strong></td>
<td>Moderate weakness affecting muscles other than ocular; may also have ocular weakness of any severity</td>
</tr>
<tr>
<td><strong>Class IIIa</strong></td>
<td>Predominantly affecting limb, axial muscles, or both; may also have lesser involvement of oropharyngeal muscles</td>
</tr>
<tr>
<td><strong>Class IIIb</strong></td>
<td>Predominantly affecting oropharyngeal, respiratory muscles, or both; may also have lesser or equal involvement of limb, axial muscles, or both</td>
</tr>
<tr>
<td><strong>Class IV</strong></td>
<td>Severe weakness affecting muscles other than ocular; may also have ocular weakness of any severity</td>
</tr>
<tr>
<td><strong>Class IVa</strong></td>
<td>Predominantly affecting limb, axial muscles, or both; may also have lesser involvement of oropharyngeal muscles</td>
</tr>
<tr>
<td><strong>Class IVb</strong></td>
<td>Predominantly affecting oropharyngeal, respiratory muscles, or both; may also have lesser or equal involvement of limb, axial muscles, or both</td>
</tr>
<tr>
<td><strong>Class V</strong></td>
<td>Defined by intubation, with or without mechanical ventilation, except when employed during routine postoperative management (intubation for management of airway = Class V)</td>
</tr>
</tbody>
</table>
<h3 id="mg-adl-activities-of-daily-living-score">MG-ADL (Activities of Daily Living) Score<a class="headerlink" href="#mg-adl-activities-of-daily-living-score" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Domain</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Talking</strong></td>
<td>Normal</td>
<td>Intermittent slurring or nasal speech</td>
<td>Constant slurring or nasal but can be understood</td>
<td>Difficult to understand speech</td>
</tr>
<tr>
<td><strong>Chewing</strong></td>
<td>Normal</td>
<td>Fatigue with solid food</td>
<td>Fatigue with soft food</td>
<td>Gastric tube</td>
</tr>
<tr>
<td><strong>Swallowing</strong></td>
<td>Normal</td>
<td>Rare episode of choking</td>
<td>Frequent choking necessitating diet changes</td>
<td>Gastric tube</td>
</tr>
<tr>
<td><strong>Breathing</strong></td>
<td>Normal</td>
<td>Shortness of breath with exertion</td>
<td>Shortness of breath at rest</td>
<td>Ventilator dependent</td>
</tr>
<tr>
<td><strong>Ability to brush teeth or comb hair</strong></td>
<td>Normal</td>
<td>Extra effort but no rest needed</td>
<td>Rest periods needed</td>
<td>Cannot do one of these functions</td>
</tr>
<tr>
<td><strong>Ability to arise from chair</strong></td>
<td>Normal</td>
<td>Mild, sometimes uses arms</td>
<td>Moderate, sometimes fails on first attempt</td>
<td>Severe, requires assistance</td>
</tr>
<tr>
<td><strong>Double vision</strong></td>
<td>None</td>
<td>Occurs but not daily</td>
<td>Daily but not constant</td>
<td>Constant</td>
</tr>
<tr>
<td><strong>Eyelid droop</strong></td>
<td>None</td>
<td>Occurs but not daily</td>
<td>Daily but not constant</td>
<td>Constant</td>
</tr>
</tbody>
</table>
<p><em>Total MG-ADL Score: 0-24. Score ‚â•6 generally indicates suboptimal control. Improvement ‚â•2 points = clinically meaningful. Validated for treatment response monitoring.</em></p>
<hr />
<h2 id="8-evidence-references">8. EVIDENCE &amp; REFERENCES<a class="headerlink" href="#8-evidence-references" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Evidence Level</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>AChR antibody testing for MG diagnosis</td>
<td>Class I</td>
<td>Gilhus NE et al. Lancet Neurol 2019</td>
</tr>
<tr>
<td>AChR binding + blocking + modulating antibodies increases sensitivity to ~95%</td>
<td>Class II</td>
<td>Howard JF. Clinical Overview of MG. UpToDate 2024</td>
</tr>
<tr>
<td>MuSK antibody testing in seronegative MG</td>
<td>Class I</td>
<td>Hoch W et al. Nat Med 2001; Evoli A et al. Brain 2003</td>
</tr>
<tr>
<td>LRP4 antibody in double-seronegative MG</td>
<td>Class II</td>
<td>Higuchi O et al. Ann Neurol 2011; Zisimopoulou P et al. J Neuroimmunol 2014</td>
</tr>
<tr>
<td>RNS: ‚â•10% decrement diagnostic criterion</td>
<td>Class I, Level A</td>
<td>AANEM Practice Parameter 2001; Sanders DB et al.</td>
</tr>
<tr>
<td>SFEMG most sensitive diagnostic test (95-99%)</td>
<td>Class I, Level A</td>
<td>Sanders DB, St√•lberg EV. Muscle Nerve 1996</td>
</tr>
<tr>
<td>Ice pack test for ocular MG (~80% sensitivity)</td>
<td>Class II, Level B</td>
<td>Cubero E et al. Neurology 2000</td>
</tr>
<tr>
<td>CT chest for thymoma screening in all MG patients</td>
<td>Class I, Level A</td>
<td>Gilhus NE et al. Lancet Neurol 2019; AAN Guidelines</td>
</tr>
<tr>
<td>Pyridostigmine as first-line symptomatic therapy</td>
<td>Class I, Level A</td>
<td>Mehndiratta MM et al. Cochrane 2011</td>
</tr>
<tr>
<td>MuSK-MG often refractory to pyridostigmine</td>
<td>Class II</td>
<td>Evoli A et al. Brain 2003; Guptill JT et al. 2011</td>
</tr>
<tr>
<td>Prednisone for MG immunosuppression</td>
<td>Class I, Level A</td>
<td>Palace J et al. Cochrane 2012</td>
</tr>
<tr>
<td>Steroid-induced transient worsening in ~50% of MG patients</td>
<td>Class II</td>
<td>Bae JS et al. Muscle Nerve 2006</td>
</tr>
<tr>
<td>Mycophenolate mofetil as steroid-sparing agent</td>
<td>Class I (negative RCTs but widely used)</td>
<td>Sanders DB et al. Neurology 2008; MG Study Group (note: RCTs were short-duration)</td>
</tr>
<tr>
<td>Azathioprine as steroid-sparing agent</td>
<td>Class I, Level B</td>
<td>Palace J et al. Cochrane 2012</td>
</tr>
<tr>
<td>TPMT testing before azathioprine</td>
<td>Class I, Level A</td>
<td>Pharmacogenomics guidelines; FDA labeling</td>
</tr>
<tr>
<td>Rituximab for MuSK-positive MG</td>
<td>Class II (observational)</td>
<td>D√≠az-Manera J et al. Neurology 2012; Hehir MK et al. Neurology 2017</td>
</tr>
<tr>
<td>Rituximab for AChR-positive refractory MG</td>
<td>Class II</td>
<td>Tandan R et al. (BeatMG trial) Lancet Neurol 2023</td>
</tr>
<tr>
<td>Eculizumab for AChR-positive generalized MG</td>
<td>Class I (REGAIN trial)</td>
<td>Howard JF et al. Lancet Neurol 2017</td>
</tr>
<tr>
<td>Ravulizumab for AChR-positive generalized MG</td>
<td>Class I (CHAMPION-MG)</td>
<td>Vu T et al. NEJM 2022</td>
</tr>
<tr>
<td>Zilucoplan for AChR-positive generalized MG</td>
<td>Class I (RAISE trial)</td>
<td>Howard JF et al. Lancet Neurol 2023</td>
</tr>
<tr>
<td>Efgartigimod for AChR-positive generalized MG</td>
<td>Class I (ADAPT trial)</td>
<td>Howard JF et al. Lancet Neurol 2021</td>
</tr>
<tr>
<td>Rozanolixizumab for AChR-positive generalized MG</td>
<td>Class I (MycarinG trial)</td>
<td>Bril V et al. Lancet Neurol 2023</td>
</tr>
<tr>
<td>IVIG for MG acute exacerbation and maintenance</td>
<td>Class I, Level A</td>
<td>Gajdos P et al. Cochrane 2012</td>
</tr>
<tr>
<td>PLEX for myasthenic crisis</td>
<td>Class I, Level A</td>
<td>Gajdos P et al. Cochrane 2012</td>
</tr>
<tr>
<td>IVIG equivalent to PLEX for MG exacerbation</td>
<td>Class I</td>
<td>Barth D et al. Cochrane 2011</td>
</tr>
<tr>
<td>Thymectomy for non-thymomatous AChR-positive MG</td>
<td>Class I (MGTX trial)</td>
<td>Wolfe GI et al. NEJM 2016</td>
</tr>
<tr>
<td>MGTX trial: thymectomy + prednisone superior at 3 years</td>
<td>Class I</td>
<td>Wolfe GI et al. NEJM 2016; 5-year extension data 2019</td>
</tr>
<tr>
<td>Medications to avoid in MG (comprehensive review)</td>
<td>Class II-III</td>
<td>Gilhus NE. NEJM 2016; Sheikh S et al. Muscle Nerve 2021</td>
</tr>
<tr>
<td>FVC &lt;15 mL/kg predicts need for intubation</td>
<td>Class II, Level B</td>
<td>Thomas CE et al. Neurology 1997</td>
</tr>
<tr>
<td>NIF weaker than -20 cm H2O: intubation threshold</td>
<td>Class II, Level B</td>
<td>Thomas CE et al. Neurology 1997</td>
</tr>
<tr>
<td>MG-ADL as validated outcome measure</td>
<td>Class I</td>
<td>Wolfe GI et al. Neurology 1999</td>
</tr>
<tr>
<td>QMG score as validated outcome measure</td>
<td>Class I</td>
<td>Barohn RJ et al. Ann NY Acad Sci 1998</td>
</tr>
<tr>
<td>MGFA Clinical Classification system</td>
<td>Consensus</td>
<td>Jaretzki A et al. Neurology 2000</td>
</tr>
<tr>
<td>Meningococcal vaccination before complement inhibitors</td>
<td>FDA requirement</td>
<td>FDA REMS for eculizumab/ravulizumab/zilucoplan</td>
</tr>
<tr>
<td>Pregnancy management in MG</td>
<td>Class II-III</td>
<td>Norwood F et al. J Neurol Neurosurg Psychiatry 2014; Batocchi AP et al. Neurology 1999</td>
</tr>
<tr>
<td>Transient neonatal MG in 10-20% of births</td>
<td>Class II</td>
<td>Hoff JM et al. Eur J Neurol 2003</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="change-log">CHANGE LOG<a class="headerlink" href="#change-log" title="Permanent link">&para;</a></h2>
<p><strong>v1.0 (January 27, 2026)</strong>
- Initial creation
- Section 1: 46 laboratory tests across 3 tiers (17 core, 18 extended, 11 rare/specialized)
  - AChR binding/blocking/modulating antibodies as core
  - MuSK, LRP4, anti-striated muscle, anti-titin, anti-RyR as extended
  - VGCC, paraneoplastic panel, CMS genetics as rare
- Section 2: Imaging and studies across 3 tiers plus bedside tests
  - CT/MRI chest for thymoma screening
  - RNS and SFEMG as electrodiagnostic studies
  - Ice pack test, rest test, bedside fatigability tests
  - FVC and NIF monitoring protocols
- Section 3: Treatment across 5 subsections
  - 3A: Cholinesterase inhibitors (7 items including pyridostigmine IR/SR/liquid, neostigmine IV)
  - 3B: Corticosteroids (9 items including gradual/rapid escalation, pulse therapy, bone/GI protection, PCP prophylaxis)
  - 3C: Steroid-sparing agents (7 items: mycophenolate, azathioprine, tacrolimus, cyclosporine, methotrexate, cyclophosphamide, maintenance IVIG)
  - 3D: Biologics and rescue (10 items: rituximab, eculizumab, ravulizumab, zilucoplan, efgartigimod IV/SC, rozanolixizumab, PLEX, IVIG rescue)
  - 3E: Surgical treatment (3 items: VATS/robotic thymectomy, sternotomy, extended thymectomy)
- Section 4: Recommendations across 5 subsections
  - 4A: 18 referrals including MG Foundation/patient advocacy
  - 4B: 18 patient instructions
  - 4C: 28 medications to avoid organized by drug class
  - 4D: 10 vaccination items including meningococcal requirements
  - 4E: 15 pregnancy considerations
- Section 5: 14 differential diagnoses
- Section 6: Monitoring parameters
  - 6A: 14 acute monitoring parameters with FVC/NIF thresholds
  - 6B: 18 chronic monitoring parameters
- Section 7: Disposition criteria (6 levels), MGFA Classification (11 classes/subclasses), MG-ADL score (8 domains)
- Section 8: 37 evidence citations</p>












                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
        
<div class="md-social">
  
    
    
    
    
      
      
    
    <a href="https://github.com/blondarb/neuro-plans" target="_blank" rel="noopener" title="github.com" class="md-social__link">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    
      
      
      <script id="__config" type="application/json">{"annotate": null, "base": "../..", "features": ["navigation.instant", "navigation.tracking", "navigation.sections", "navigation.expand", "navigation.top", "search.suggest", "search.highlight", "content.code.copy"], "search": "../../assets/javascripts/workers/search.2c215733.min.js", "tags": null, "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}, "version": null}</script>
    
    
      <script src="../../assets/javascripts/bundle.79ae519e.min.js"></script>
      
        <script src="../../assets/js/comments.js"></script>
      
    
  </body>
</html>